Uppsala, Sweden, April 09, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, will host a conference call on April 12 at 14:00 CEST to present final Cantrixil Phase 1 data set to be released at the 2021 AACR annual meeting.

The call will be hosted by CEO Francois Martelet and CSO Reinhard Koenig. The presentation will be in English.

The conference call will be broadcast live on the web via the link:
https://tv.streamfabriken.com/press-conference-2021-9

Telephone number for the conference call is:
SE: +46851999383
UK: +443333009260
US: +18338230590

For More Information: 

Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Oasmia’s proprietary drug delivery platform which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com.

Attachments

Oasmia Announces Conference Call to Present Cantrixil Final Phase I Data to be released at the 2021 AACR Annual Meeting

© Modular Finance, source Nordic Press Releases